What the Research Says
Conjugated Linoleic Acid (CLA) is a well-researched supplement for weight management, supported by numerous randomized controlled trials (RCTs) and comprehensive meta-analyses. A 2007 meta-analysis by Whigham et al. demonstrated that CLA supplementation leads to modest fat loss, with an average effect of approximately 0.05 kg/week of fat loss. This effect is consistent over long periods, as shown in a study by Gaullier et al. (2004). Importantly, CLA may help preserve lean mass while reducing fat mass, which explains why it does not typically result in significant reductions in scale weight.
Recent studies have expanded on the effects of CLA beyond weight management. A 2023 systematic review by Liang et al. highlighted that exercise can enhance the body composition benefits of CLA supplementation. Additionally, a 2023 meta-analysis by Rastgoo et al., involving 42 studies, found that CLA supplementation can influence inflammatory markers and adipokines, suggesting potential broader health benefits.
However, safety considerations are important. A 2022 systematic review by Asbaghi et al., analyzing 56 RCTs, reported that while CLA supplementation significantly increases HDL-C levels, it also raises TG, TC, LDL-C, apolipoprotein A, and B concentrations, which may pose risks for individuals with lipid abnormalities. Furthermore, studies by Suksatan et al. (2022) and Haghighat et al. (2022) indicate that CLA may affect oxidative stress markers and liver function enzymes, though the clinical significance of these findings remains unclear.
Overall, while CLA shows promise for modest fat loss and potential metabolic benefits, its use should be approached with caution, particularly in at-risk populations, and under medical supervision.